Edition:
United Kingdom

People: Ligand Pharmaceuticals Inc (LGND.OQ)

LGND.OQ on NASDAQ Stock Exchange Global Market

184.89USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$184.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
128,172
52-wk High
$277.48
52-wk Low
$126.77

Patel, Sunil 

Mr. Sunil Patel is Independent Director of the Company. He has more than 20 years of senior management and R&D experience in the biotechnology industry. Mr. Patel most recently was Executive Vice President and Chief Financial Officer for OncoMed Pharmaceuticals, a development-stage company focused on therapeutics targeting cancer stem cells. Mr. Patel has held senior management positions in corporate development, marketing, and strategy with BiPar Sciences, Allos Therapeutics, Connetics, Abgenix and Gilead Sciences. Mr. Patel also worked at McKinsey & Company serving biotech and pharmaceutical clients and has held scientific research positions at ZymoGenetics and ProCyte. Mr. Patel received his undergraduate degree in Chemistry at the University of California, Berkeley, and master’s degree in Molecular Bioengineering/Biotechnology at the University of Washington. In selecting Mr. Patel to serve as a director, the board considered, among other things, his valuable pharmaceutical and corporate development experience, including his service at OncoMed Pharmaceuticals. Ligand also benefits from Mr. Patel’s experience in serving as a senior member of management at both public and private biotechnology companies.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 75,591
Long-Term Incentive Plans, USD --
All Other, USD 191,199
Fiscal Year Total, USD 266,790

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Kozarich

291,078

Matthew Foehr

3,458,500

John Higgins

5,513,210

Matthew Korenberg

2,185,720

Charles Berkman

1,498,820

Jason Aryeh

277,156
As Of  31 Dec 2017